Pack size: 1 Capsule  |  Price is for the whole Capsule

⚠ Prescription required. This medicine may only be dispensed against a valid prescription.

Generic: Ibrutinib

Form: Capsule 140mg

Indication

Ibrutinib, is a kinase inhibitor indicated for the treatment of patients with: • Mantle cell lymphoma (MCL), who have received at least one prior therapy Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials. • Chronic lymphocytic leukemia (CLL), who have received at least one prior therapy • Chronic lymphocytic leukemia with 17p deletion • Waldenström’s macroglobulinemia (WM)

Administration

Administer once daily at approximately the same time each day. Capsules should be taken orally with a glass of water. The capsules should not be opened, broke, or chewed.

Adult Dose

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenström Macroglobulinemia 420 mg taken orally once daily (three 140 mg capsules once daily) Mantle Cell Lymphoma 560 mg taken orally once daily (four 140 mg capsules once daily) Hepatic impairment Mild (Child Pugh class A): 140 mg PO qDay Moderate-to-severe (Child Pugh Classes B and C): Avoid use

Child Dose

Safety and efficacy not established

Contraindication

Hypersensitivity. Concomitant use w/ St. John's wort-containing prep.

Mode of Action

Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK’s role in signaling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro.